Healthcare - Biotechnology - NASDAQ - US
$ 8.01
-8.98 %
$ 445 M
Market Cap
-4.77
P/E
INCOME STATEMENT
34.2 M
REVENUE
-108 M
OPERATING INCOME
-98.4 M
NET INCOME
EFFICIENCY
Earnings Waterfall
Foghorn Therapeutics Inc.
| Revenue | 34.2 M |
| Cost Of Revenue | 110 M |
| Gross Profit | -75.5 M |
| Operating Expenses | 142 M |
| Operating Income | -108 M |
| Other Expenses | -9.48 M |
| Net Income | -98.4 M |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Revenue | 34.2 | 19.2 | 1.3 | 0.4 | 0 | 0 |
| GROSS PROFIT | ||||||
| Cost Of Revenue | 109.7 | 19.2 K | 7.5 | 57.7 | 1.8 | 0.4 |
| Gross Profit | (75.5) | 19.2 | (6.2) | (57.3) | (1.8) | (0.4) |
| OPERATING INCOME | ||||||
| Operating Expenses | 142.1 | 136.4 | 102.1 | 69.0 | 51.1 | 26.0 |
| Selling, General and Administrative Expenses | 32.4 | 30.7 | 21.7 | 11.2 | 6.7 | 4.8 |
| Research and Development Expenses | 109.7 | 105.6 | 80.3 | 57.7 | 44.4 | 21.2 |
| Operating Income | (107.9) | (117.1) | (100.7) | (68.5) | (51.1) | (26.0) |
| PRE-TAX INCOME | ||||||
| Interest Income Expense | 0 | 0 | 1.9 | 1.0 | 0.5 | 0.4 |
| Total Other Income | 13.7 | 8.3 | (0.6) | (0.3) | 44 K | (0.3) |
| Pre-Tax Income | (94.2) | (108.9) | (101.3) | (68.8) | (51.1) | (26.3) |
| NET INCOME | ||||||
| Tax Provision | 4.2 | 8.26 K | 1.9 | 1.0 | 0.5 | 83 K |
| Net Income | (98.4) | (108.9) | (103.2) | (69.8) | (51.7) | (26.3) |
| EPS | 2.34 | 2.62 | 2.78 | 1.9 | 1.4 | 1.34 |